Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SP0273
- Development stage
- Phase 2
- Lead developer
- Sanofi
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
**SP0273** was Sanofi's investigational quadrivalent messenger RNA seasonal influenza vaccine program, developed from the Translate Bio mRNA platform. It used mRNAs encoding influenza hemagglutinin antigens to induce humoral and cellular immune responses against influenza A and influenza B viruses following intramuscular administration. The program included MRT5407 and MRT5410 clinical candidates evaluated in Phase 1/2 studies in adults. Sanofi identified a need to improve influenza B-strain immune responses and subsequently removed SP0273 from development. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05553301))
- Other names
- quadrivalent influenza mRNA vaccine
02
Targets
HA0 (Influenza B virus hemagglutinin)HA (Hemagglutinin)
Beyond the preview
Go deeper on SP0273.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SP0273.